Abstract:Objectives: A Patterns of Care Study (PCS) was performed in the largest regional medical center in Zhejiang Province, China. The hospital information system (HIS) was used to evaluate patient characteristics and changes in initial treatment patterns for prostate cancer and to determine recent predominant trends in treatment plans for prostate cancer (PCa) in China. Methods: Men who were newly diagnosed with localized or locally advanced PCa for 2010-2011 and 2016-2017 were identified in the HIS database. Patient characteristics and temporal trends in initial management were assessed, and differences between groups were evaluated for significance using Chi-square and Mann-Whitney U tests. Results: In total, 1792 patients met the study criteria, including 505 and 1287 patients in the 2010-2011 and 2016-2017 samples, respectively. The average age of patients diagnosed in the 2010-2011 PCS survey was 70 years, decreasing to 68 years when the 2016-2017 patients were included (P<0.001). In the 2010-2011 sample, 50.69% of the patients had an initial prostate-specific antigen (PSA) level ≥20 ng/ml. In contrast, the initial PSA level was 4-19.99 ng/ml for 66.67% of the patients in the 2016-2017 sample (P<0.001). Based on National Comprehensive Cancer Network (NCCN) criteria, the percentages of patients in low- and intermediate-risk groups increased from 33.06% to 54.78%; conversely, the percentages in high-risk, very high-risk, and regional (N1) groups decreased to a certain extent (P<0.001). According to European Association of Urology (EAU) criteria, the percentages of patients in low- and intermediate-risk groups increased from 32.07% to 53.69%, yet the percentage in the high-risk group decreased (P<0.001). The use of radical prostatectomy (RP) and radiation therapy (RT) increased from 48.32% to 76.46% and 5.35% to 16.94%, particularly in high-risk and low-risk groups, respectively, whereas the rates of hormone therapy (HT) and active surveillance and observation (AS&O) decreased from 32.28% to 4.27% and from 16.04% to 2.33%, respectively (P<0.001). A similar pattern was observed when patients were stratified by EAU risk group. Conclusions: The results of this real-world study in the largest regional medical center in Zhejiang Province, China, indicate that the predominant characteristics of PCa patients and trends in initial management are changing rapidly. We found the following: (a) a trend toward a decreased age among newly diagnosed patients; (b) a trend toward lower initial PSA levels; (c) a downward trend in risk group classification; (d) a significant increase in the likelihood of receiving RP, particularly in the high-risk group; (e) an increase in the rate of RP, mostly due to use of the Da Vinci robotic system; (f) a significant increase in the likelihood of receiving RT, especially in the low-risk group; and (g) a decrease in HT and AS&O.

PCN52 Disease Burden of Prostate Cancer UNDER Current Treatment Pattern in China

PCN43 Disease Burden of NON-SMALL CELL Cancer UNDER Current Treatment Pattern in China

Comparison of the clinicopathologic features of prostate cancer in US and Chinese populations

PCN49 Disease Burden of Classical Hodgkin Lymphoma UNDER Current Treatment Pattern in China

PCN47 Disease Burden of Gastric Cancer UNDER the Current Treatment Pattern in China

PCN50 Disease Burden of Chronic Myeloid Leukemia UNDER Current Treatment Pattern in China

PCN46 Disease Burden of Chronic Lymphocytic Leukemia/SMALL Lymphocytic Lymphomaunder Current Treatment Pattern in China

Prognosis of Prostate Cancer and Bone Metastasis Pattern of Patients: a SEER-based Study and a Local Hospital Based Study from China

Trends in Treatment for Prostate Cancer in China: Preliminary Patterns of Care Study in a Single Institution

Burden of Prostate Cancer in China, 1990–2019: Findings From the 2019 Global Burden of Disease Study

PCN44 Disease Burden of Follicular Lymphoma UNDER the Current Treatment Pattern in China

PCN21 Disease Burden of Multiple Myeloma UNDER the Current Treatment Pattern in China

PCN26 Disease Burden of ACUTE Myelogenous Leukemia UNDER the Current Treatment Pattern in China

Health Care Utilization and Costs of Patients with Prostate Cancer in China Based on National Health Insurance Database from 2015 to 2017.

PCN15 Disease Burden of Myelodysplastic Syndrome UNDER the Current Treatment Pattern in China

PCN51 Disease Burden of Mantle CELL Lymphoma UNDER Current Treatment Pattern in China

PCN198 THE BURDEN OF ESOPHAGEAL CANCER IN CHINA FROM 2013 TO 2030: A DYNAMIC COHORT MODELING STUDY

PCN14 Disease Burden of Waldenstrom's Macroglobulinemia UNDER the Current Treatment Pattern in China

PIN24 Disease Burden of Progressive Chronic Hepatitis C in China

Prostate Cancer in Asia: A Collaborative Report

Management of Prostate Cancer in China: a Multicenter Report of 6 Institutions.